NCT06926634View on ClinicalTrials.gov

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2034

Study Completion Date

October 31, 2034

Conditions

High Grade Neuroendocrine Neoplasms

Interventions

DRUG

Zanzalintinib

Provided by Exelixis

Trial Locations (2)

55905

Mayo Clinic - Rochester, Rochester

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Exelixis

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT06926634 - Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs) | Biotech Hunter | Biotech Hunter